- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | HCW Biologics approves reverse stock split to meet Nasdaq rules | 3 | Investing.com | ||
| Di | HCW Biologics genehmigt Aktienzusammenlegung zur Erfüllung der NASDAQ-Vorschriften | 4 | Investing.com Deutsch | ||
| Di | HCW Biologics, Inc: HCW Biologics Announces 1-for-40 Reverse Stock Split | 1 | GlobeNewswire (USA) | ||
| Fr | HCW Biologics GAAP EPS of -$0.08 misses by $0.17, revenue of $0.39M misses by $6.61M | 4 | Seeking Alpha | ||
| Fr | HCW Biologics Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Fr | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | HCW Biologics, Inc: HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results | 610 | GlobeNewswire (Europe) | MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 19.03. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | HCW Biologics, Inc: HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements | 97 | GlobeNewswire (Europe) | MIRAMAR, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 06.03. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.02. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.02. | What's Going On With HCW Biologics Stock Monday? | 1 | Benzinga.com | ||
| 03.02. | HCW Biologics Gets Clearance Form FDA To Initiate Phase 1 Study Of HCW9302 In Alopecia Areata | 2 | RTTNews | ||
| 03.02. | FDA genehmigt HCW Biologics Studie für Alopezie-Behandlung | 12 | Investing.com Deutsch | ||
| 03.02. | HCW Biologics, Inc: HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial | 111 | GlobeNewswire (Europe) | MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 03.02. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.01. | HCW Biologics, Inc: HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 | 2 | GlobeNewswire (USA) | ||
| 23.12.24 | HCW Biologics, Inc: HCW Biologics Inc. Received NASDAQ Staff Determination Letter | 130 | GlobeNewswire (Europe) | Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE... ► Artikel lesen | |
| 23.12.24 | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.11.24 | HCW Biologics Inc. - 8-K, Current Report | 3 | SEC Filings |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,451 | -0,88 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
| BIOXXMED | 0,320 | -16,88 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| ORGANOVO | 2,210 | 0,00 % | Organovo, Inc.: Organovo Provides Business Update | SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| OCUGEN | 0,615 | +2,33 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA ZSB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIRONA BIOCHEM CORP.... ► Artikel lesen | |
| BIO-GATE | 0,765 | +2,68 % | Bio-Gate: Vielversprechende Wachstumschancen | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im Geschäftsjahr 2024 (per 31.12.) einen leichten Umsatzrückgang verbucht, besitzt aufgrund der innovativen... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,718 | 0,00 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
| VAXART | 0,369 | +6,40 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,280 | +1,45 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,059 | -4,50 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| AFFIMED | 0,930 | -100,00 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting | MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
| IMMUNIC | 1,008 | +2,08 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,116 | +1,75 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,082 | 0,00 % | T2 Biosystems, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| CEL-SCI | 0,215 | +6,03 % | CEL-SCI Aktie: Risiken mehren sich | CEL-SCI hat am 18. März 2025 den Abschluss eines Finanzierungsangebots in Höhe von 2,5 Millionen Dollar bekannt gegeben. Dabei wurden 16 Millionen Stammaktien oder vorfinanzierte Optionsscheine ausgegeben.... ► Artikel lesen |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,281 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.
